Dogma Biotech
New therapies through genetic minimalism
We enable minimalist glycans that meet or surpass nature’s therapeutic efficacy, as confirmed by biopharma in animal studies.
Artificial intelligence + synthetic biology
Cracking the glycosylation code
Unlike standard biotech, which replicates human glycosylation, our AI-driven platform creates minimalist glycans that rival or surpass natural performance. Hidden within an unexplored "dark" glycomics space lies vast therapeutic potential—Dogma Biotech is bringing it to light.
Enabling proteins therapies
5x faster and cheaper, with 2X therapeutic benefits
By bypassing complex glycosylation, we unlock therapies that were previously constrained by intricate modifications. At the same time, our streamlined post-translational modifications boost host-cell productivity, cutting protein manufacturing costs by up to 5X.
Traction
preclinically validated
In partnership with a European biopharma, Dogma Biotech conducted animal studies comparing its minimalist glycans to the best commercially available therapy. Results showed that Dogma’s glycan-modified proteins matched or exceeded the efficacy of current treatments, highlighting their potential for cost-effective and transformative therapeutic solutions.
Let's build a glycosylated future
Contact us
Our scientific team has over 15 years of expertise in the area of glyco-engineering. While deeply entrenched in our field, we are non-conformists. We are challenging a fundamental paradigm of glycol-biology and cracking the glycosylation code for better and innovative therapies.